Comprehensive effects of supplemented essential amino acids in patients with severe COPD and sarcopenia

R.W. Dal Negro1,2, R. Aquilani3, S. Bertacco1, F. Boschi4, C. Micheletto1, S. Tognella1


Aim. Aim of the study was to investigate whether or not oral supplementation of essential amino acids (EAAs) may improve body composition, muscle metabolism, physical activity, cognitive function, and health status in a population of subjects with severe chronic obstructive pulmonary disease (COPD) and sarcopenia.

Methods. Thirty-two patients (25 males) (FEV1/FVC <40% predicted), age 75±7 years, were randomised (n=16 in both groups) to receive 4 gr/bid EAAs or placebo according to a double-blind design. When entered the study (T0), after four (T4), and after twelve (T12) weeks of treatments, body weight, fat free-mass (FFM), plasma lactate concentration (µmol/l), arterial PaCO2 and PaO2, physical activity (n° steps/day), cognitive function (Mini Mental State Examination; MMSE), health status (St.George’s Respiratory Questionnaire; SGRQ) were measured.

Results. EAAs supplemented, but not patients assuming placebo, progressively improved all baseline variables over-time. In particular, at T12 of EAAs supplementation, body weight (BW) increased by 6 Kg ($p=0.002$), FFM by 3.6 Kg ($p=0.05$), plasma lactate decreased from 1.6 µmol/l to 1.3 µmol/l ($p=0.023$), PaO2 increased by 4.6 mmHg ($p=0.01$), physical activity increased by 80% ($p=0.01$). Moreover, the score for cognitive dysfunction improved from 19.1 scores to 20.8 ($p=0.011$), while the SGRQ score also improved from 72.3 to 69.6 even though this trend did not reach the statistical significance.

Conclusions. A three-month EAAs supplementation may have comprehensive effects on nutritional status; muscle energy metabolism; blood oxygen tension, physical autonomy; cognitive function, and perception of health status in patients with severe COPD and secondary sarcopenia. Monaldi Arch Chest Dis 2010; 73: 1, 25-33.

Keywords: Essential Amino Acids supplementation, Sarcopenia, COPD.

1 U.O.C. di Pneumologia, ULSS22 Regione Veneto, Ospedale Orlandi, Bussolengo, Verona.
2 Centro Nazionale Studi di Farmacoeconomia e Farmacoepidemiologia Respiratoria, Verona.
3 Metabolic Service and Nutritional Pathophysiology, Salvatore Maugeri Foundation, Montescano, Pavia.
4 Department of Experimental & Applied Pharmacology, University of Pavia, Pavia, Italy.

Correspondence: Dal Negro Roberto W., U.O.C.di Pneumologia, ULSS22 Regione Veneto, Ospedale Orlandi, Bussolengo (Verona), Italy; e-mail: rdalnegro@ulss22.ven.it

Introduction

Chronic obstructive pulmonary disease (COPD) is often associated with substantial weight loss and reduced skeletal mass and function [1-3]. The prevalence becoming underweight is 35-60% of patients with moderate-to-severe COPD whereas muscle wasting occurs in 20% of stable COPD [1, 4-5].

Weight loss and muscle wasting contribute to a reduction in physical performance and can lead to disability [6]. In advanced COPD, the loss of body weight and the deterioration of muscle mass/function represent independent predictors of morbidity and mortality [7-9]. Furthermore, cachexia, the extreme form of ‘underweight’ (usually defined by a lean body mass index (LBMD) <16 Kg/m2 in males and <15 Kg/m2 in females) [10], reduces the survival rate by half after adjustments for spirometric severity of COPD [10].

Consequently, therapeutic strategies aimed at reversing this particular outcome are of great interest in terms of both patient’s prognosis and quality of life. To date, this topic has been adopted by nutritional interventions; pharmacotherapies, and physical training, even though all these options are still proving to have significant limits.

Studies carried out on adding nutritional supplementation to an eight-week integrated pulmonary rehabilitation showed a significant improvement of body weight (BW) associated with a longer survival [11]; an increased fat free mass (FFM); maximal inspiratory pressure; handgrip strength, exercise capacity [12] in a proportion of patients investigated. Conversely, a larger population of patients do not show any benefit from an intensive, integrated, long-term rehabilitation.

Interventional studies that have looked at newer pharmacological approaches (such as: anti-in-
Whole body physical training, a further support to COPD treatment, was found to induce an anabolic response and an increase of BW by increasing FFM [18]; nevertheless, weight-losing patients are unable to perform an intensive physical having aimed at improving FFM. In addition, low FFM is not the only factor involved in reduced aerobic capacity [19] as reduced peripheral blood flow; impaired energy metabolism with increased rate of anaerobic metabolism, and lactate production may play a further relevant role [20].

In the present study we hypothesised that those limitations could be overcome by a supplementation of simple nutritional substrates, such as essential amino acids (EAAs). By our suggestion, the effects of EAAs on patient with COPD could partially surrogate (or contribute to) the effects of a long-term, intensive, integrated rehabilitation [12]. Actually, EAAs could improve body weight and FFM; peripheral muscle energy metabolism, and exercise capacity. The rationale of using EAAs derives from studies documenting the role of amino acids in regulating protein synthesis [21]; enhancing aerobic metabolism [22], and biological activities of anabolic hormones such as insulin and insulin-like growth factor-1 (IGF-1) [23, 24]. We also formulated a second hypothesis, that EAAs could improve per se the deterioration of both cognitive dysfunction and health status perception [25], which are highly prevalent in COPD [26]. This hypothesis is mainly based on the biological property of several amino acids to act as precursor of brain neurotransmitters [27] involved in cognition, motor function, mood.

Methods

Thirty-two consecutive out-patients (twenty-seven males) suffering from stable severe COPD (GOLD class 3-4) complicated with sarcopenia and to be tested for cognitive dysfunction were recruited and randomly assigned to EEAs (Aminotrofic, and to be tested for cognitive dysfunction were recruited and randomly assigned to EEAs (Aminotrofic, which are highly prevalent in COPD [26]. Patients were checked in baseline (T0); after four (T4), and after twelve (T12) weeks of treatment. Variables collected at all the experimental times were:

- FEV1 and FVC (measured in liters and % predicted), and FEV1/FVC (%) (Masterscreen Body Jaeger/Carefusion, Hoechberg, Germany);
- \( \text{PaO}_2 \) and \( \text{PaCO}_2 \) (mmHg); HbO2, and lactate (mmol/l) in arterial blood samples drawn anaerobically from the left radial artery (ABL 735 Analyzer, Radiometer, Copenhagen, DK);
- BMI and the fat free mass (FFM, Kg) via impedimentometric body composition analysis (Tanita BC-420 MA; Tanita Corp., Tokyo, Japan);
- total protein and albumin concentration (g/l) in blood;
- the dyspnoea score (MRC scale);
- the Mini Mental Questionnaire score;
- Quality of Life assessed in baseline and at the end of both the twelve-week treatments by the St. George Respiratory Questionnaire (SGRQ);
- total number steps were measured daily at home during patients’ free-living by the SenseWear Armband PRO3 (BodyMedia; Pittsburgh, PA, USA), continuously worn by the patients for one week in baseline, and during each fourth week of both treatments.

In baseline, lung function was also preliminary assessed before and thirty minutes after salbutamol 400mcg in order to check the patients’ short-term reversibility (% change FEV1 from baseline).

Statistics

Descriptive statistics (mean ± standard deviation) were reported for all the analysed variables. Baseline characteristics of the EAA supplemented group vs. placebo were compared by means of a Student’s \( t \) test for unpaired data. A repeated measures analysis of variance model with one factor (Group) was applied to evaluate trends over time for all the collected variables. Statistical significance was expressed as the value of the time*Group interaction, testing the different trends between patients belonging to the placebo or treated group. The Bonferroni post-hoc test was also used to check any difference among different time points within and between curves. As significance level of \( p<0.05 \) has been accepted.

Results

Patients’ characteristics in baseline

After randomisation, the two groups of sarcopenic COPD patients were well matched in terms of baseline lung function; body weight and body composition; skeletal muscle metabolism; physical activity; cognitive dysfunction, and altered perception of their health status (table 1). Both groups of patients were also comparable in terms of increased plasma lactic acid levels,
with an average value 5-fold the upper limit for our laboratory, thus indicating the prevalence of a glucose anaerobic metabolism within their muscle tissue, and suggesting the existence of a cell energy storage. Their similarity in body weight and fat free mass was expected since patients were selected for being sarcopenic. To note that all patients were characterised by a substantial reduction of their physical activity, being the total number of steps just about 600 daily.

Patients also showed a reduction in liver protein synthesis of comparable extent as indicated by a serum albumin concentration lower than 35g/l. Furthermore, their cognitive status proved equally mildly deteriorated as suggested by the Mini Mental State Examination Test (MMSE), with a basal score of 19 in the placebo and 20 in the EAAs group, respectively. Finally, all patients perceived their health status and quality life as very poor.

Table 1. - Description of the variables in the two groups of patients after randomisation of placebo or EAA supplementation

<table>
<thead>
<tr>
<th>Variables</th>
<th>nv</th>
<th>Placebo group</th>
<th>EAA supplemented group</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male/Female</td>
<td>–</td>
<td>11/5</td>
<td>14/2</td>
<td>–</td>
</tr>
<tr>
<td>Age (years)</td>
<td>–</td>
<td>75±7</td>
<td>75±7</td>
<td>–</td>
</tr>
<tr>
<td><strong>Anthropometric</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BW (Kg)</td>
<td>–</td>
<td>54.38±7</td>
<td>53.75±6.4</td>
<td>0.8</td>
</tr>
<tr>
<td>BMI (Kg/m²)</td>
<td>–</td>
<td>20.2±1.8</td>
<td>20.2±1.4</td>
<td>0.97</td>
</tr>
<tr>
<td>LBMI (Kg/m²)</td>
<td>–</td>
<td>14.92±2</td>
<td>15.3±1.94</td>
<td>0.58</td>
</tr>
<tr>
<td><strong>Body composition</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FFM (Kg)</td>
<td>–</td>
<td>39.86±4.8</td>
<td>40.46±3.8</td>
<td>0.70</td>
</tr>
<tr>
<td>FM (Kg)</td>
<td>–</td>
<td>14.52±2.3</td>
<td>13.29±2.6</td>
<td>0.8</td>
</tr>
<tr>
<td><strong>Serum protein</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total proteins (g/l)</td>
<td>65-80</td>
<td>61.57±5.15</td>
<td>61.7±3.2</td>
<td>0.93</td>
</tr>
<tr>
<td>Albumin (g/l)</td>
<td>35-50</td>
<td>33.16±2.7</td>
<td>32.94±3.7</td>
<td>0.68</td>
</tr>
<tr>
<td><strong>Pulmonary function</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV₁ (l/sec)</td>
<td>–</td>
<td>0.84±0.15</td>
<td>0.90±0.21</td>
<td>0.34</td>
</tr>
<tr>
<td>FEV₁/FVC (%)</td>
<td>–</td>
<td>38±11.5</td>
<td>39±7.18</td>
<td>0.58</td>
</tr>
<tr>
<td><strong>Blood gas tension</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PaO₂ (mmHg)</td>
<td>80-100</td>
<td>60.15±4.88</td>
<td>61.28±8.3</td>
<td>0.64</td>
</tr>
<tr>
<td>PaCO₂ (mmHg)</td>
<td>35-45</td>
<td>46.28±7.6</td>
<td>45±6</td>
<td>0.61</td>
</tr>
<tr>
<td><strong>Oxygen saturation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HbO₂ (%)</td>
<td>–</td>
<td>94.32±0.96</td>
<td>94.38±2</td>
<td>0.91</td>
</tr>
<tr>
<td><strong>Muscle metabolism</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma lactate (µmol/l)</td>
<td>-0.5±0.5</td>
<td>1.73±0.27</td>
<td>1.63±0.68</td>
<td>0.62</td>
</tr>
<tr>
<td><strong>Daily walking</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steps (n°)</td>
<td>–</td>
<td>609.81±45.72</td>
<td>602.25±65.58</td>
<td>0.97</td>
</tr>
<tr>
<td><strong>Cognitive function</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMSE (score)</td>
<td>≥24</td>
<td>20.19±3.52</td>
<td>19.12±4.6</td>
<td>0.47</td>
</tr>
<tr>
<td><strong>Health status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SGRQ (score)</td>
<td>–</td>
<td>71.44±6.98</td>
<td>72.25±8.52</td>
<td>0.77</td>
</tr>
</tbody>
</table>

Data is expressed as main ± standard deviation (SD).

Statistical analysis: Student’s t test for unpaired data; placebo group vs EAA supplemented group.

BW: body weight; BMI: Body Mass Index; LBMI: Lean Body Mass Index, FFM: fat-free mass; FM: fat mass; FEV₁: forced expiratory volume in one second; FVC: forced vital capacity, PaO₂: partial pressure of oxygen; PaCO₂: Partial pressure of carbon dioxide; HbO₂: oxygen saturation; MMSE: Mini Mental State Examination test; SGRQ: St.George’s Respiratory Questionnaire. nv: normal value.
**Patients’ characteristics after intervention**

The time courses of variables obtained after placebo or EAAs supplementation showed that patients assuming EAAs, but not those assuming placebo, progressively improved their nutritional status: muscle metabolism; oxemia, daily physical activity; cognitive capacity, and perception of health status (table 2, figure 1).

At the end of the study (T12), a substantial EAAs-associated increase in both body weight (+6 Kg; +11%) and FFM (+3.6 Kg; +8.9%); a drop in lactate plasma levels (from 1.6±0.7 µmol/l to 1.3±0.6 µmol/l) was also observed, even if the corresponding absolute values still remained higher than the reference normal values (-0.5/+0.5 µmol/l).

An unexpected increase in baseline blood oxygen tension (PaO2 +4.6 mmHg; +75%) was found at T12; interestingly, the improvement in PaO2 was not associated with a concomitant improvement in PaCO2.

Furthermore, EAAs supplementation was associated with an increased physical autonomy at T12, resulting the baseline patients’ daily physical activity improving by 80%. However, even if significantly ameliorated, their physical activity still remained severely limited.

Moreover, at the end of the study, EAAs supplementation induced a significant increase in protein synthesis which changed from the basal value of 32.7g/l to 37g/l (+4.3g/l).

Finally, both the cognitive dysfunction and particularly the negative perception of their health state were significantly ameliorated only in EAAs supplemented patients; as concerning the latter aspect, the SGRQ score proved systematically improved from baseline (average drop of -2.7 points) even if it did not reach the four-point variation which is needed for claiming a substantial and effective benefit in patients’ quality of life.

**Discussion**

**Baseline patient characteristics**

The present investigation proved that sarcopenia may be associated with exalted muscle anaerobic metabolism and reduced visceral protein synthesis in stable, severe COPD patients at rest. This biochemical condition is confirmed by the high plasma lactate levels and the low serum albumin concentration measured. Moreover, the presence of hyperlactatemia indirectly indicates that the muscle metabolism efficiency in producing energy was basally reduced.

These results are in line with those from previous studies that found a reduced muscle concentrations of energy substrates and cofactors [28] in COPD patients. Actually, several factors (such as, systemic inflammation; hypoxia, and muscle disuse) can cause an increased rate of muscle anaerobic metabolism in COPD [29].

In particular, it has been proved that inflammation is able to induce cytokine production [30, 31] which can affect muscle glucose metabolism by reducing pyruvate oxidation [32]. Furthermore, hypoxia not only can affect glucose transport in axial skeletal muscles [33], but can also lead cell metabolism shifting from aerobic metabolism to the anaerobic one [34], while a low physical activity further impairs muscle aerobic metabolism [35]. The presence of this condition may be suggested in most disabled patients, such as those with severe limitations in washing, dressing, or walking less that 600 steps per daily.

In general terms, the consequences of an increased muscle anaerobic metabolism are deleterious for both the nutritional state and the exercise capacity. Firstly, lactate-induced cell acidosis leads to an exalted somatic and myofibrillar proteolysis [36]. Moreover, a cellular energy shortage can reduce both the muscle protein synthesis [37] and the physical activity as suggested by the negative correlation between plasma lactate and the number of steps performed by the patients in baseline conditions. Consequently, skeletal muscles of sarcopenic COPD patients are exposed to increased muscle catabolism continuously.

The reduction in serum albumin concentrations, which reflects a reduced liver synthesis rate of non-reactant proteins, may be regarded as secondary to a chronic inadequacy in protein caloric intake and/or the effect of systemic inflammation with a shift of liver protein synthesis from non-reactant proteins to the inflammatory ones [38]. It is possible that hypoxia contributed to reduce both FFM and albumin synthesis as it stimulates tumour necrosis factor alpha production [30, 31].

Patients of this study led a very sedentary lifestyle. Alterations in their body composition; ventilatory limitation [19]; muscle energy short-age; and muscle cell acidosis can likely represent factors which contributed to their impaired physical anatomy.

The present investigation also highlights the presence of a substantial basal cognitive dysfunction in the study population. This is in agreement with data from other important studies which demonstrated the presence of an higher rate of cognitive impairment [26] and a lower cognitive performance in standardised measurement overtime [25] among adults with COPD. It has also been suggested that this cognitive deterioration tends to reflect the severity of the COPD-induced pulmonary dysfunction [25]. Other studies linked the severity of the cognitive deterioration to the extent of lung function impairment in terms of FEV1 [39], and to brain perfusion abnormalities secondary to hypoxemia [40]. However, although we did not find any significant correlation between oxemia, lactate and cognitive test, the impaired blood gas pressures could have influenced the performance in cognitive test [41].

The clinical consequences of altered cognition can be relevant for COPD patients because cognitive dysfunction may further reduce patient adherence to therapeutic programs; enhance patients’ disability, and decrease their quality of life [42].
Table 2 - Mean ± SD and statistical analysis between placebo and EAA supplemented patients

<table>
<thead>
<tr>
<th>Variables</th>
<th>Placebo group</th>
<th>T4 vs T0</th>
<th>T12 vs T0</th>
<th>EAA group</th>
<th>T4 vs T0</th>
<th>T12 vs T0</th>
<th>Interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>PaCO2 (mmHg)</td>
<td>T0: 46.28±7.6</td>
<td>T4: 46.21±3.88</td>
<td>ns</td>
<td>T12: 45.47±4.87</td>
<td>T0: 45.32±6</td>
<td>T4: 45.32±5.22</td>
<td>ns</td>
</tr>
<tr>
<td></td>
<td>T0: 60.15±4.88</td>
<td>T4: 58.12±4.58</td>
<td>ns</td>
<td>T12: 57.14±4.14</td>
<td>T0: 61.56±8.5</td>
<td>T4: 62.20±6.28</td>
<td>ns</td>
</tr>
<tr>
<td>sO2</td>
<td>T0: 94.32±0.96</td>
<td>T4: 93.98±1.71</td>
<td>ns</td>
<td>T12: 94±1.73</td>
<td>T0: 94.6±1.86</td>
<td>T4: 92.75±2.76</td>
<td>ns</td>
</tr>
<tr>
<td>FEV1 (l/sec)</td>
<td>T0: 0.84±0.15</td>
<td>T4: 0.78±0.16</td>
<td>ns</td>
<td>T12: 0.75±0.15</td>
<td>T0: 0.90±0.22</td>
<td>T4: 0.90±0.22</td>
<td>ns</td>
</tr>
<tr>
<td>FEV1% (%)</td>
<td>T0: 38±11.49</td>
<td>T4: 37.61±12.9</td>
<td>ns</td>
<td>T12: 36.13±10.33</td>
<td>T0: 39.62±7.35</td>
<td>T4: 39.5±7.20</td>
<td>ns</td>
</tr>
<tr>
<td>Lactate (µmol/l)</td>
<td>T0: 1.73±0.27</td>
<td>T4: 1.8±0.35</td>
<td>ns</td>
<td>T12: 1.95±0.36</td>
<td>T0: 1.65±0.70</td>
<td>T4: 1.43±0.30</td>
<td>ns</td>
</tr>
<tr>
<td>FFM (Kg)</td>
<td>T0: 39.86±4.82</td>
<td>T4: 39.95±3</td>
<td>ns</td>
<td>T12: 39.73±2.78</td>
<td>T0: 40.41±4</td>
<td>T4: 41.56±4.51</td>
<td>ns</td>
</tr>
<tr>
<td>BW (Kg)</td>
<td>T0: 54.38±6.95</td>
<td>T4: 54±6.82</td>
<td>ns</td>
<td>T12: 53.31±5.77</td>
<td>T0: 53.47±6.53</td>
<td>T4: 55.4±8.44</td>
<td>ns</td>
</tr>
<tr>
<td>LBMI (Kg/m2)</td>
<td>T0: 14.91±2</td>
<td>T4: 14.97±1.73</td>
<td>ns</td>
<td>T12: 14.89±1.63</td>
<td>T0: 15.34±2</td>
<td>T4: 15.7±1.51</td>
<td>ns</td>
</tr>
<tr>
<td>BMI (Kg/m2)</td>
<td>T0: 20.21±1.80</td>
<td>T4: 20±1.65</td>
<td>ns</td>
<td>T12: 19.9±1.69</td>
<td>T0: 20.16±1.43</td>
<td>T4: 20.82±2.34</td>
<td>ns</td>
</tr>
<tr>
<td>Steps (°)</td>
<td>T0: 609.81±454.72</td>
<td>T4: 651.94±557.88</td>
<td>ns</td>
<td>T12: 562.88±601.87</td>
<td>T0: 638.8±661.8</td>
<td>T4: 880.20±836.60</td>
<td>ns</td>
</tr>
<tr>
<td>Serum total proteins (g/l)</td>
<td>T0: 61.57±5.15</td>
<td>T4: 60.35±5.17</td>
<td>ns</td>
<td>T12: 60.94±5.12</td>
<td>T0: 62.20±2.66</td>
<td>T4: 63.83±3.96</td>
<td>ns</td>
</tr>
<tr>
<td>Serum albumin (g/l)</td>
<td>T0: 33.16±2.71</td>
<td>T4: 32.49±3.43</td>
<td>ns</td>
<td>T12: 33.28±4.39</td>
<td>T0: 32.94±3.67</td>
<td>T4: 35.14±3.51</td>
<td>p=0.001</td>
</tr>
<tr>
<td>MMT (score)</td>
<td>T0: 20.19±3.52</td>
<td>T4: 19.62±3.59</td>
<td>ns</td>
<td>T12: 19.44±3.68</td>
<td>T0: 19.13±4.6</td>
<td>T4: 19±3.9</td>
<td>ns</td>
</tr>
<tr>
<td>SGRQ (score)</td>
<td>T0: 71.44±6.98</td>
<td>T4: –</td>
<td>ns</td>
<td>T12: 72.81±7</td>
<td>T0: 72.25±8.52</td>
<td>T4: –</td>
<td>ns</td>
</tr>
</tbody>
</table>

Data is expressed as mean ± standard deviation.
Statistical analysis: Anova test.
T0: baseline; T4: after 1 months; T12: after 3 months.
EAA group: essential amino acid supplemented group.
PaO2: partial pressure of oxygen; PaCO2: Partial pressure of carbon dioxide; sO2: oxygen saturation; FEV1: forced expiratory volume1; FVC: forced vital capacity; FFM: fat-free mass; BW: body weight; LBMI: Lean Body Mass Index; BMI: Body Mass Index; MMT: Mini Mental State Examination test; SGRQ: St.George’s Respiratory Questionnaire.
Effects of EAAs on patient variables

EAAS AND BODY COMPOSITION

The 3.6 Kg improvement in FFM following EAAs supplementation is impressive when considering the 1.1 Kg gain of FFM obtained after a 8-week period of pulmonary rehabilitation [12].

It is interesting to note that the 10% increase in FFM observed in the present study after EAAs supplementation is close to the 11.8% increase in skeletal mass obtained in patients suffering from COPD after a two-month supplementation with the same formula used in the current investigation [43]. Nevertheless, the increase obtained in body weight (+6 Kg) in the present study is higher than that obtained in previous investigations showing a weight stability after a nutritional supplementation (+570 Kcal from carbohydrates; via 800 mg/day of...
megestrol acetate for eight weeks) combined with pulmonary rehabilitation [44]. This difference can likely be related to the characteristics of the substrate used because megestrol is known to mainly increase fat mass (FM) and not muscle tissue, being mechanisms underlining the effects of EAAs both direct and indirect.

In fact, EAAs directly stimulate protein synthesis [45] and inhibit proteolysis [46] in several tissue including skeletal muscle and the liver. The peculiarity of EAAs in these districts may explain the amelioration of both FFM and albumin synthesis. To note that EAA-promoted protein synthesis is independent of insulin [21]: this feature represents a relevant aspect particularly for those COPD patients with insulin-resistance and following a long-term corticosteroid therapy, and/or during acute exacerbations. In addition, the stimulation of protein anabolism by EAAs could benefit sarcopenic patients with diminished circulating levels of anabolic hormones including testosterone, growth hormone and insulin-like growth factor (IGF-1) [47].

EAAs may indirectly exert their activity on muscle and liver protein synthesis by augmented the biological activity of IGF-1 [24].

**EAAs and muscle metabolism**

The study proved that EAAs supplementation, but not placebo, is associated with a significant reduction in plasma lactate (figure 1). The improvement in lactate formation could be due to the effects of EAAs on muscle metabolism as EAAs can stimulate the aerobic energy-producing pathway [37] both directly by entering the aerobic cycle as alternative substrate [37], and indirectly by shifting lactate pyruvate reaction to the right [37]. In this way EAAs could overcome the block of glucose aerobic oxidation caused by pro-inflammatory cytokines via the aerobic metabolism re-activation [32].

**EAAs and daily physical activity**

Data from the present study also proved the progressive improvement in daily physical activity in EAAs-supplemented patients, even though their physical autonomy remained greatly limited, being the total steps daily performed by supplemented EAAs about 1085 after a three-month supplementation.

The improvement in patients’ walking capacity may be related to several factors including the improvement in their nutritional state, aerobic metabolism, body anabolism (albumin). All these factors can also ameliorate patients’ motivation to physical activity. The different mechanisms contributing to improve physical capacity may likely account for the absence of any significant relationship between lactatemia and physical activity that we found at the patients’ randomisation time. An important factor that could improve the physical activity might be the increase in muscle strength, not measured in the study. It is reasonable to presume the amelioration of muscle strength as patients ameliorated both their FFM and aerobic metabolism.

**EAAs and blood oxygen tension**

The gradual improvement in PaO2 following EAAs was unexpected. A speculative explanation is that the improvement in PaO2 could be due to EAA influence on cardiac function [48] which can ameliorate pulmonary blood flux/distribution. A better oxemia may be crucial for COPD evolution as it should reduce the stimulus to cytokine production and decrease the release of both interleukin 1 and tumour necrosis factor alpha in human alveolar macrophages [49]. Reduction of chronic hypoxemia may also contribute to increase FFM and body weight in the patients of the study.

**EAAs and cognition and health status**

The increase in blood oxygen tension may enhance brain perfusion that on the contrary is reduced by chronic hypoxia [41]; brain hypoperfusion is also hypothesised to affect cognitive performance in these patients [40]. Moreover, we tend to emphasize that the EAAs-associated improvement in cognition should be related to both the oxemia amelioration and the increased availability of neurotransmitters’ amino acids precursors in the brain. In fact, amino acids used in the present study contain several precursors of brain neurotransmitters that play an important role in cognition, motor function and mood [50], such as: brain norepinephrine, dopamine, epinephrine transmitters derived from tyrosine; serotonin from tryptophan; acetylcholine from methionine; histamine from histidine. It is important to note that the brain of hypoxic COPD subjects need an increased amount of neurotransmitter precursors as hypoxia facilitates per se the circulating levels of catecholamines through mechanisms involving the increased synthesis and/or release [51, 52] of acetylcholine [53].

The improvement in the patient perception of health status may be a consequence of the increased body weight and FFM; body anabolic orientation (total protein and albumin synthesis); higher oxemia, and reduction in cognitive impairment.

The amelioration of cognition and health status could have relevant clinical consequences which include improvements in patient adherence to treatment and maintenance of their independence over time [25].

**Clinical perspectives**

Results of the present study accord with data from two recent studies carried out on cachectic COPD [54] and on muscle-depleted patients with chronic heart failure [55] which were both supplemented with the same aminoacid formula (at the same dose) as that used in the present investigation.
The study suggests that EAAs might results particularly useful in those COPD patients who cannot undergo to rehabilitation for any reason, or cannot perform any intensive physical training due to the presence of severe comorbidities, or to the subject subject’s frailty being too severe. 

It is also plausible that EAAs may act synergistically with rehabilitation and optimise corresponding outcomes in terms of the recovery of nutritional status, cognitive dysfunction and quality of life in severe COPD patients with sarcopenia.

Limitations of the study

We are aware that the present study has some limitations. First, the small number of the patients’ sample precluded any conclusion on possible gender-related difference in the results.

Second, patients were not investigated in terms of their daily nutritional intake, and this particular aspect might be relevant when evaluating the possible role of EAA supplementation in affecting protein caloric intake effectively.

Finally, patients were not followed after EAA discontinuation and then we can not draw any conclusion on maintenance of changes overtime. Conversely, the study was planned only with the aim of investigating whether or not EAAs could have any impact on sarcopenic condition of severe COPD patients.

In conclusion, even if further larger investigations are needed in the future to face specifically all these aspects and validate present data, the actual results from the present study emphasizethat a three-month EAAs supplementation in sarcopenic patients with severe COPD can lead to a substantial improvements in the patient’s body weight and body composition; peripheral muscle anaerobic metabolism; oxemia; daily physical activity; cognitive function, and perception of their own health status.

References

24. Jousse C, Bruhat A, Ferrara M, Fatourmous P. Physio- logical concentration of amino acids regulates insulin-


Scognamigli R, Negut C, Palisi M, Dioguardi FS, Coccato M, Iliceto S. Effects of oral amino acid supplements on cardiac function and remodeling in patients with type 2 diabetes with mild-to-moderate left ventricular dysfunction. Am J Cardiol 2008; 101: 111E-115E.


